FountainVest Partners’ US$900 Million Acquisition of Langdi Pharmaceutical

Goodwin Procter advised FountainVest Partners on the deal. FountainVest Partners announced the acquisition of China-based Beijing Zhendong Langdi Pharmaceutical Co., Ltd. for approximately US$900 million. FountainVest is...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here